Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
FDA Votes Against Proposed
FDA Votes Against Proposed Blenrep Treatment Combo’s for Multiple Myeloma
UC San Diego Expands Its Capacity
UC San Diego Expands Its Capacity to Test Innovative Treatments for Disease
Simvastatin Does Not Enhance Escitalopram
Data Show Simvastatin Does Not Enhance Escitalopram Response in Comorbid Depression and Obesity
MAIA Biotechnology
MAIA Biotechnology publishes preclinical data on cancer drug candidates
Zanubrutinib Outperforms Acalabrutinib in Adjusted Head-to-Head Analysis
An adjusted analysis of the ALPINE and ASCEND trials revealed a statistically significant progression-free survival advantage for Zanubrutinib.
FDA Announces Plan to Phase Out Animal Testing. Will That Work?
Human organs-on-chips and organoids offer new alternatives to animals for drug development, but there is still a long way to go.
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
FDA to review MSD’s doravirine/islatravir NDA for HIV-1
FDA to review MSD’s doravirine/islatravir NDA for HIV-1
FDA Receives Resubmitted BLA
FDA Receives Resubmitted BLA for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease
Aviva Biopharm Inc.
Aviva Biopharm Inc. Unveils Groundbreaking Pre-Clinical Data on d3-T, a First-in-Class Testosterone Therapy for Women at ENDO 2025
FDA Grants Orphan Drug Designation to Quemliclustat in Pancreatic Cancer
Quemliclustat plus gemcitabine and nab-paclitaxel chemotherapy outperformed median OS benchmarks in patients with metastatic PDAC.
FDA-approved drug can reduce post-surgery pain without heavy opioid use
Researchers at the Medical University of South Carolina have made a breakthrough in pain management.
60
61
62
63
64
65
66
67
68